Biochemical and pharmacologic properties of 2614W94, a reversible, competitive inhibitor of monoamine oxidase-A

Drug Development Research

Volumn 45, Issue 1, 1998, Pages 1-9

  White, Helen L ^a,e   Scates, Philip W ^a,b   Harrelson, Jane C ^a,b   Johnson, Thomas E ^a   Norton, Ron M ^a,b   Jones, Stacey A ^a,b   Rigdon, Greg C ^a,c   Hughes, John E ^a   Cooper, Barrett R ^a,d   Harfenist, Morton ^a,d  

^a Burroughs Wellcome Co   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Icagen Inc   (United States)

^d ICAgen Inc ^*  (United States)

^e Krenitsky Pharmaceuticals Inc   (United States)

Author keywords

2614W94; Biogenic amines; Enzyme inhibition; Monoamine oxidase; Serotonin; Structure activity relationships

Indexed keywords

3 (1 TRIFLUOROMETHYL)ETHOXYPHENOXATHIIN 10,10 DIOXIDE; 5 HYDROXYTRYPTOPHAN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DOPAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; NORADRENALIN; SEROTONIN; TYRAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG TRANSPORT; ENZYME INACTIVATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STEREOISOMERISM;

EID: 0032444746     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199809)45:1<1::AID-DDR1>3.0.CO;2-2     Document Type: Article

References (14)

1. Bach WJ, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan S-W, Seeburg PU, Shih JC. 1988. cDNA cloning of human liver monoamine oxidase A and B: molecular differences between two forms of the enzyme. Proc Natl Acad Sci USA 85:4934-4938.
2. Bieck PR. Antonin KH. 1989. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs. irreversible inhibitors. J Neural Transm Suppl 28:21-31.
3. Brown CS, Bryant SG. 1988. Monoamine oxidase inhibitors: safety and efficacy issues. Drug Intell Clin Pharm 22:232-235.
4. Burchall CJ, Soroko FE, Rigdon GC. 1992. Potentiation of the behavioral effects of 5-hydroxytryptophan by BW 1370U87, a selective monoamine oxidase-A inhibitor. Drug Dev Res 25:209-213.
5. Carroll M, Beek O. 1992. Blood pressure effects of monoamine oxidase inhibitors in response to orally administered tyramine in the rat. Drug Dev Res 25:215-218.
6. Christmas AJ, Coulson CJ, Maxwell DR, Riddell D. 1972. A comparison of the pharmacological and biochemical properties of substrate-selective monoamine oxidase inhibitors. Br J Pharmacol 45:490-503.
7. Da Prada M, Kettler R, Burkard WP, Haefely WE. 1984. Moclobemide, an antidepressant with short-lasting MAO-A inhibition: brain catecholamines and tyramine pressor effects in rats. In: Tipton KE, Dostert P, Strolin-Benedetti M, editors. Monoamine oxidase and disease. New York: Academic Press, p 137-154.
8. Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely WE. 1989. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248:400-414.
9. Denney RM, Denney CB. 1985. An update on the identity crisis of monoamine oxidase: new and old evidence for the independence of MAO-A and B. Phannacol Ther 30:227-259.
10. Freeman H. 1993. Moclobemide. Lancet 342:1528-1532.
11. Harrelson JC, Johnson TE, White HL. Welch RM. 1992. Metabolism of BW 1370U87 in rat, dog, and man. Drug Dev Res 25:219-227.
12. Jones-Humble SA, Norton RM, White HL, Cooper BR. 1992. BW 1370U87, a new monoamine oxidase-A inhibitor: effects on biogenic amine neurotransmitter and metabolite levels in rat brain. Drug Dev Res 25:201-207.
13. Korn A, Eichler HG, Fischbach R, Gasic S. 1986. Moclobemide, a new reversible MAO inhibitor: interaction with tyramine and tricyclic anlidepressants in healthy volunteers and depressive patients. Psychophannacology (Berl) 88:153-157.
14. Lan NC, Chen C, Shih JC. 1989. Expression of functional human monoamine oxidase A and B cDNAs in mammalian cells. J Neurochem 52:1652-1654.